0Y5E Stock Chart & Stats
$10.22
$0.05(0.49%)
At close: 4:00 PM EDT
$10.22
$0.05(0.49%)
Day’s Range― - ―
52-Week Range$9.28 - $24.49
Previous CloseN/A
Volume701.00
Average Volume (3M)766.00
Market Cap
$1.40B
Enterprise Value$4.45K
Total Cash (Recent Filing)$399.70M
Total Debt (Recent Filing)$3.29B
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Nov 11, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend Yield11.41%
Share Statistics
EPS (TTM)-12.51
Shares Outstanding138,367,770
10 Day Avg. Volume972
30 Day Avg. Volume766
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.45
P/FCF Ratio13.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.00Price Target Upside66.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.14
Revenue Forecast (FY)$4.06B
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained positive operating and free cash flow provides durable internal funding for dividends, capex, and debt reduction even while accounting earnings are weak. This cash-generation capacity supports strategic flexibility and funds the operational enhancement program without relying solely on external financing.
Operational Execution & Share GainsMaterial improvements in service levels and execution strengthen retailer relationships and shelf availability, which are durable advantages in private-label OTC. Consistent service gains and modest market share growth in the U.S. and Europe improve competitive positioning and support more stable revenue capture over multiple quarters.
Portfolio Simplification And Debt ReductionThe deliberate portfolio simplification and use of divestiture proceeds to pay down borrowings materially reduce structural leverage risk and allow management to focus on core self-care categories. Preserving capital discipline via targeted sales enhances long-term balance-sheet resilience and strategic clarity.
Bears Say
Revenue Decline & LossesA sustained decline in revenue combined with material operating and net losses signals durable execution and demand challenges. Shrinking top line constrains operating leverage, limits reinvestment capacity, and increases the reliance on nonrecurring actions to restore profitability over the coming quarters.
Elevated LeverageLeverage materially above parity despite recent reductions leaves the company exposed to interest and refinancing risk and reduces financial flexibility. With profitability weak, servicing elevated debt limits the ability to fund investment and increases sensitivity to adverse demand or cost shocks over the medium term.
Margin Pressure & Under-absorptionSustained gross margin compression and a sizable planned under-absorption EPS headwind reflect structural volume shortfalls and cost absorption challenges. Even with cost programs, these factors materially erode earnings power and make near-term margin recovery dependent on durable volume growth and execution improvements.
Perrigo Company News
0Y5E FAQ
What was Perrigo Company plc’s price range in the past 12 months?
Perrigo Company plc lowest share price was $9.28 and its highest was $24.49 in the past 12 months.
What is Perrigo Company plc’s market cap?
Perrigo Company plc’s market cap is $1.40B.
When is Perrigo Company plc’s upcoming earnings report date?
Perrigo Company plc’s upcoming earnings report date is Nov 11, 2026 which is in 93 days.
How were Perrigo Company plc’s earnings last quarter?
Perrigo Company plc released its earnings results on Aug 05, 2026. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of $0.388 by $0.112.
Is Perrigo Company plc overvalued?
According to Wall Street analysts Perrigo Company plc’s price is currently Undervalued.
Does Perrigo Company plc pay dividends?
Perrigo Company plc pays a Quarterly dividend of $0.29 which represents an annual dividend yield of 11.41%. See more information on Perrigo Company plc dividends here
What is Perrigo Company plc’s EPS estimate?
Perrigo Company plc’s EPS estimate is 0.52.
How many shares outstanding does Perrigo Company plc have?
Perrigo Company plc has 138,367,770 shares outstanding.
What happened to Perrigo Company plc’s price movement after its last earnings report?
Perrigo Company plc reported an EPS of $0.5 in its last earnings report, beating expectations of $0.388. Following the earnings report the stock price went up 24.131%.
Which hedge fund is a major shareholder of Perrigo Company plc?
Currently, no hedge funds are holding shares in GB:0Y5E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perrigo Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.00 (66.34% Upside)
$17.00 (66.34% Upside)
Blogger Sentiment
Bullish
GB:0Y5E Sentiment 80%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.28%
12-Months-Change
Fundamentals
Return on Equity
11.41%
Trailing 12-Months
Asset Growth
-18.20%
Trailing 12-Months
Company Description
Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
0Y5E Company Deck
0Y5E Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational progress and strategic actions against ongoing top-line and margin pressures. Positive indicators include market share gains, substantial service-level improvements, a recovering Infant Formula business (+23% sales, +$60M operating income), acceleration of a scalable innovation pipeline, targeted cost-savings ($80–$100M program) and the use of $359M divestiture proceeds to reduce debt. Offsetting these positives were a 3%+ decline in net sales, 250 basis points of gross margin compression, notable retailer destocking (≈1.8% headwind), specialty segment weakness and an expected ~$0.60 EPS headwind in 2026 from under-absorption. Management maintained full-year guidance and emphasized that results are weighted to a stronger second half, signaling cautious optimism but acknowledging remaining execution and demand risks.View all GB:0Y5E earnings summaries0Y5E Stock 12 Month Forecast
Average Price Target
$17.00
▲(66.34% Upside)
Technical Analysis
Viatris
―
Supernus Pharmaceuticals
―
Teva Pharmaceutical
―
Indivior
―
Amneal Pharmaceuticals
―